Medicenna Therapeutics Corp.(Toronto Stock Exchange : MDNA)
MDNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||5.98%||12.76||0.7%||$891.97m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.27%||187.85||1.9%||$517.31m|
|GILD||Gilead Sciences, Inc.||-0.91%||66.61||1.0%||$493.35m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.36%||537.92||2.7%||$384.81m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.40%||180.69||2.0%||$338.92m|
|EXAS||EXACT Sciences Corp.||-0.30%||126.52||18.1%||$189.07m|
|TXG||10X Genomics, Inc.||-2.18%||194.43||0.0%||$173.74m|
|BNGO||Bionano Genomics, Inc.||-3.05%||7.62||0.0%||$165.33m|
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.